Skip to main content

Table 5 Repeated measures mixed model analysis assessing individual predictors of the EQ-5D summary score and EQ-5D VAS

From: Association between work time loss and quality of life in patients with Herpes Zoster: a pooled analysis of the MASTER studies

 

EQ-5D Item

EQ-5D overall summary score

EQ-5D VAS

Predictor

Estimatea

SD

95% CI for estimate

p-value

Estimatea

SD

95% CI for estimate

p-value

Work Time Loss Category

 Work Time Lossb vs. No Work Time Loss

−0.234

0.010

−0.254, −0.215

<0.001

−16.92

0.755

−18.40, −15.44

<0.001

Time from HZ onset - categorical

 Prevalent vs. incident

−0.049

0.014

−0.076, −0.022

<0.001

−3.811

1.339

−6.442, −1.181

0.005

Age category at rash onset, yearsc

 60–69 vs. 50–59

−0.002

0.015

−0.032, 0.028

0.898

−1.562

1.465

−4.441, 1.318

0.287

  ≥ 70 vs. 50–59

−0.042

0.026

−0.092, 0.008

0.100

−2.785

2.472

−7.643, 2.073

0.260

Worst Pain Categoryc,d

 Moderate vs. mild

−0.084

0.013

−0.111, −0.058

<0.001

−8.842

1.075

−10.95, −6.732

<0.001

 Severe vs. mild

−0.287

0.018

−0.323, −0.251

<0.001

−14.08

1.447

−16.92, −11.24

<0.001

Severity of rash (number of lesions)c

 Mild (1–20) vs.no rash

0.109

0.017

0.074, 0.143

<0.001

10.646

1.707

7.292, 14.000

<0.001

 Moderate (21–50) vs. no rash

0.100

0.021

0.058, 0.141

<0.001

8.892

2.064

4.837, 12.947

<0.001

 Severe (>50) vs. no rash

0.095

0.024

0.049, 0.142

<0.001

9.684

2.278

5.207, 14.160

<0.001

Genderc

 Male vs. female

−0.005

0.013

−0.032, 0.021

0.691

0.833

1.295

−1.711, 3.377

0.520

Impaired immune statusc, e

 Yes vs. no

−0.034

0.025

−0.084, 0.016

0.181

−1.876

2.472

−6.734, 2.983

0.448

Presence of complications from HZc

 Yes vs. no

−0.012

0.014

−0.040, 0.016

0.400

−5.016

1.370

−7.707, −2.324

<0.001

Employment statusc

 Full time vs. part time

0.008

0.016

−0.024, 0.040

0.612

−1.919

1.574

−5.011, 1.173

0.223

Geographic regionc,f

 Latin America vs. Asia

0.030

0.017

−0.004, 0.064

0.191

3.245

1.628

0.047, 6.443

0.098

 North America vs. Asia

−0.043

0.017

−0.076, −0.010

0.011

−5.146

1.583

−8.257, −2.035

0.001

Country category (income)c, g

 High vs. Upper Middle

−0.052

0.014

−0.079, −0.026

<0.001

−6.616

1.290

−9.151, −4.081

<0.001

  1. SD standard deviation, CI confidence interval, HZ Herpes Zoster, WPQ Work and Productivity Questionnaire, ZBPI Zoster Brief Pain Inventory, VAS visual analogue scale, CIS carcinoma in situ, HIV human immunodeficiency virus, AIDS acquired immune deficiency syndrome
  2. aThe estimate is the relative effect of the predictor on EQ-5D scores compared to the reference group
  3. bPatients with Work Time Loss were defined as those who reported missing work due to their shingles episode (entire day or part of a day) at baseline, or at any of the follow-up visits (Visits 2–10) as assessed by the WPQ
  4. cPredictors were adjusted by Work Time Loss Category
  5. dWorst pain score categories are based on the ZBPI “worst pain in the last 24 h” scores: mild worst pain = ZBPI scores 0- ≤ 3; moderate worst pain = ZBPI scores 4- ≤ 7; severe worst pain = ZBPI score ≥8
  6. e Defined as: use of high dose oral corticosteroids, invasive cancers (with the exception of CIS and non-melanoma skin cancer), HIV infection/ AIDS, immune deficiency, chemotherapy for cancer, prior or concurrent immunosuppressive therapy, and therapy for organ transplant
  7. fAsia = Taiwan, Thailand, South Korea; Latin America = Argentina, Brazil, Costa Rica; Mexico; North America = Canada
  8. gCountry income classifications are based on the 2016 World Bank economic definitions [22]. High Income= Canada, South Korea, Taiwan, Argentina; Upper Middle Income= Brazil, Costa Rica, Mexico, Thailand
Back to article page

Health and Quality of Life Outcomes

ISSN: 1477-7525

Contact us